www.mediafax.ro/economic/heineken-ingrijorata-ca-m

Heineken has warned UK pubs and bars to adapt to the rising use of weight-loss drugs, or risk losing customers and revenue. The company highlighted that GLP-1 medications, like Ozempic and Wegovy, can decrease alcohol consumption. Heineken suggests promoting smaller beer servings and low-alcohol options to counteract potential sales declines. The alcohol industry is already facing challenges with declining sales due to health-conscious consumer behavior. Heineken is monitoring changes in consumer habits related to these medications, noting that users tend to drink less but still consume alcohol in smaller quantities. Other beverage producers have varying views on the impact of these drugs on sales.